Postneoadjuvant Trastuzumab Deruxtecan Results in Higher Likelihood of iDFS Among Patients with HER2-positive EBC with Residual Invasive Disease After Neoadjuvant Treatment By Ogkologos - December 12, 2025 316 0 Facebook Twitter Google+ Pinterest WhatsApp Findings from the interim analysis of the DESTINY-Breast05 study Source RELATED ARTICLESMORE FROM AUTHOR New Targeted Therapy Shows Promising Early Results in Advanced Pancreatic Cancer FDA Approves Pivekimab Sunirine-pvzy for Blastic Plasmacytoid Dendritic Cell Neoplasm, an Ultra-Rare Haematologic Malignancy Ivonescimab Plus Chemotherapy Improves OS Compared with Tislelizumab Plus Chemotherapy in Previously Untreated Patients with Advanced Squamous NSCLC MOST POPULAR Olive Oil Found to Reduce Risk of Death from Dementia, Cancer,... January 13, 2022 Cómo prepararse para su exploración por TEP-TC April 1, 2021 Dabrafenib–Trametinib Combination Approved for Solid Tumors with BRAF Mutations July 21, 2022 6-Yr-Old With Cerebral Palsy Receives Dream Gift After Learning To Walk. January 9, 2020 Load more HOT NEWS Maintenance Regorafenib Significantly Delays Disease Progression After First-Line Treatment in Patients... FDA Approves Nivolumab in Combination with Chemotherapy for Metastatic Gastric Cancer... ESMO Targeted Anticancer Therapies Congress 2025, Paris, France, 3-5 March Study Finds Possible New Treatment for Metastatic Breast Cancer That Has...
